Synthesis, Structural Reassignment, and Antibacterial Evaluation of 2,18-Seco-Lankacidinol B
Ian Seiple investigated the synthesis and structure of 2,18-seco-Lankacidinol B.
Bacteria are becoming increasingly resistant to antibiotics in all parts of the world. New resistance mechanisms are emerging and spreading globally, thus threatening our capacity to treat even the most common infectious diseases. While bacterial infections such as pneumonia, tuberculosis and sepsis are becoming harder, and sometimes impossible, to treat as antibiotics currently in use become less effective, there is a growing need for new classes of antibiotics which can overcome resistance.
The group of Professor Ian Seiple from the University of California, San Francisco (USA) has a longstanding interest in antibiotics that inhibit protein synthesis by binding to the catalytic center of the bacterial ribosome. These include many FDA-approved classes such as the streptogramins, oxazolidinones, macrolides, lincosamides, pleuromutilins and amphenicols.